SOURCE: MacroPore Biosurgery

June 14, 2005 02:00 ET

MacroPore Biosurgery to Chair Regenerative Medicine Panel at the BIO Annual International Convention

SAN DIEGO CA -- (MARKET WIRE) -- June 14, 2005 -- MacroPore Biosurgery, Inc. (Frankfurt: XMP) announced today that Marc H. Hedrick, M.D., President of MacroPore Biosurgery, will chair a round table discussion entitled, "Bringing Regenerative Medicine to the Clinic: Cardiovascular Disease as a Case Study," on Wednesday, June 22, 2005 at 9:30 a.m. Eastern Daylight Time, at BIO 2005, the Biotechnology Industry Organization's Annual International Convention, in Philadelphia, PA.

This forum will examine the development of regenerative therapies using cardiovascular disease as a case study. Within regenerative medicine, cardiovascular disease ranks as one of the most studied conditions. This is evidenced by the multiple ongoing clinical and preclinical studies in the United States and abroad using adult stem cells, progenitor cells, skeletal myoblasts and molecular therapies. The panel will examine the latest advances of cellular- and molecular-based therapies for targeting cardiovascular disease, regulatory and reimbursement considerations and relevant business and commercialization opportunities and strategies.

About MacroPore Biosurgery, Inc.

MacroPore Biosurgery specializes in the discovery and development of regenerative medicine therapies. The Company has two principal technology platforms, adipose-derived regenerative cells and bioresorbable implants. The Company is developing treatments for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery using stem and regenerative cells from adipose tissue. This tissue is the richest and most accessible known source for regenerative cells. To facilitate the processing and delivery of adipose-derived regenerative cells, the Company is designing a proprietary point-of-care system, Celution™, to isolate and concentrate a patient's own regenerative cells in real-time. Additionally, MacroPore Biosurgery manufactures the HYDROSORB™ family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed exclusively through Medtronic, Inc. For more information, please visit http://www.macropore.com.

Contact Information

  • Contact:

    Tom Baker
    U.S. Investors/Media
    Tel. +1-858-362-0361
    Email Contact

    Stefanie Bacher
    International Investors
    Tel. +1-858-362-0365
    Email Contact